BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack) readouts ·
  AssetMemo
X-WR-CALDESC:Upcoming readouts of Avutometinib/defactinib (Avmapki Fakzynja
  Co-Pack)\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05798507-11026@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 1 readout
  est. (NCT05798507)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 1.\n
 Study: Identification of Treatment Concentrations of Defactinib or VS-6766
  for the Treatment of Patients With Glioblastoma\nEstimated primary comple
 tion: 3 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/avutometinib-defactinib-avmapki-fakzynja-co-pack#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05798507
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05787561-11026@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 2 readout
  est. (NCT05787561)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 2.\n
 Study: A Study of Avutometinib (VS-6766) and Defactinib in People With Mes
 onephric Gynecologic Cancer\nEstimated primary completion: March 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/avutometinib-defactinib-
 avmapki-fakzynja-co-pack#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05787561
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06394804-11026@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 2 readout
  est. (NCT06394804)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 2\, 
 Ovarian Cancer.\nStudy: A Study of Avutometinib\, Defactinib\, and Letrozo
 le in People With Low-Grade Serous Ovarian Cancer\nEstimated primary compl
 etion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/av
 utometinib-defactinib-avmapki-fakzynja-co-pack#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06394804
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07747506-11026@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 2 readout
  est. (NCT07747506)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 2\, 
 Ovarian Cancer.\nStudy: Continued Access to Avutometinib in Combination Wi
 th Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (
 LGSOC)\nEstimated primary completion: 1 August 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-c
 o-pack#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07747506
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06007924-11026@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20270816
DTEND;VALUE=DATE:20270817
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 2 readout
  est. (NCT06007924)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 2.\n
 Study: A Study of Avutometinib and Defactinib in People With Thyroid Cance
 r\nEstimated primary completion: 16 August 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-pa
 ck#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6007924
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05512208-11026@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 2 readout
  est. (NCT05512208)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 2\, 
 Ovarian Cancer.\nStudy: A Phase 2 Study of Avutometinib (VS-6766) Plus Def
 actinib\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-
 co-pack#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05512208
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05608252-11026@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 1/2 reado
 ut est. (NCT05608252)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 1/2.
 \nStudy: VS-6766+Abema+Fulv in Met HR+/HER- BC\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /avutometinib-defactinib-avmapki-fakzynja-co-pack#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05608252
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-11026@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 2 readout
  est. (NCT02465060)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 2.\n
 Study: Targeted Therapy Directed by Genetic Testing in Treating Patients W
 ith Advanced Refractory Solid Tumors\, Lymphomas\, or Multiple Myeloma (Th
 e MATCH Screening Trial)\nEstimated primary completion: 31 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/avutometinib-defactin
 ib-avmapki-fakzynja-co-pack#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06194929-11026@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 1/2 reado
 ut est. (NCT06194929)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 1/2.
 \nStudy: Defactinib and Avutometinib\, With or Without Encorafenib\, for t
 he Treatment of Patients With Brain Metastases From Cutaneous Melanoma\nEs
 timated primary completion: 15 January 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-pack#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06194
 929
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318324-11026@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 1 readout
  est. (NCT07318324)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 1.\n
 Study: Phase Ib Study of Avutometinib\, Defactinib\, and Everolimus in RAS
  Pathway Mutant Endometrial Cancer\nEstimated primary completion: 1 August
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/avutometinib-d
 efactinib-avmapki-fakzynja-co-pack#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07318324
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06072781-11026@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20281015
DTEND;VALUE=DATE:20281016
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 3 readout
  est. (NCT06072781)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 3\, 
 Ovarian Cancer.\nStudy: A Study of Avutometinib (VS-6766) + Defactinib (VS
 -6063) in Recurrent Low-Grade Serous Ovarian Cancer\nEstimated primary com
 pletion: 15 October 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/avutometinib-defactinib-avmapki-fakzynja-co-pack#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06072781
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07778602-11026@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20281110
DTEND;VALUE=DATE:20281111
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 1 readout
  est. (NCT07778602)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 1.\n
 Study: Safety and Feasibility of First-line Avutometinib and Defactinib in
  Patients With Newly Diagnosed High-grade Gliomas\nEstimated primary compl
 etion: 10 November 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/avutometinib-defactinib-avmapki-fakzynja-co-pack#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07778602
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06487221-11026@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 2 readout
  est. (NCT06487221)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 2.\n
 Study: Avutometinib and Defactinib in Diffuse Gastric Cancer\nEstimated pr
 imary completion: 30 November 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-pack#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06487221
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07020221-11026@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 1/2 reado
 ut est. (NCT07020221)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 1/2.
 \nStudy: A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated S
 olid Tumors\nEstimated primary completion: December 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzy
 nja-co-pack#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07020221
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06369259-11026@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 2 readout
  est. (NCT06369259)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 2.\n
 Study: Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combina
 tion With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unrese
 ctable\, Anti-EGFR-Refractory Advanced Colorectal Cancer\nEstimated primar
 y completion: 1 February 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-pack#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06369259
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06495125-11026@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20290317
DTEND;VALUE=DATE:20290318
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 2 readout
  est. (NCT06495125)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 2.\n
 Study: Defactinib\, Avutometinib and Nivolumab for the Treatment of Anti-P
 D1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer\nEstimated p
 rimary completion: 17 March 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-pack#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06495125
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07824960-11026@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 1/2 reado
 ut est. (NCT07824960)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 1/2.
 \nStudy: Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination T
 herapy in Pancreatic Adenocarcinoma\nEstimated primary completion: April 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/avutometinib-def
 actinib-avmapki-fakzynja-co-pack#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07824960
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06630260-11026@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 1/2 reado
 ut est. (NCT06630260)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 1/2.
 \nStudy: 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours\n
 Estimated primary completion: 30 September 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-pa
 ck#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6630260
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07126158-11026@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 2 readout
  est. (NCT07126158)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 2.\n
 Study: Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in A
 dvanced Pancreatic Adenocarcinoma\nEstimated primary completion: 30 April 
 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/avutometinib-de
 factinib-avmapki-fakzynja-co-pack#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07126158
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743554-11026@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 2 readout
  est. (NCT07743554)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 2.\n
 Study: Combination of Avutometinib and Defactinib for Treatment of Relapse
 d\, Refractory\, Metastatic\, or Unresectable Malignant Peripheral Nerve S
 heath Tumor\nEstimated primary completion: January 2031. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzyn
 ja-co-pack#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07743554
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
